Sangamo Therapeutics (SGMOQ) Change in Accured Expenses (2010 - 2025)

Sangamo Therapeutics' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at -$1.5 million for Q4 2025.

• On a quarterly basis, Change in Accured Expenses fell 140.89% year-over-year to -$1.5 million in Q4 2025; TTM through Dec 2025 was $2.8 million, a 51.35% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 51.35% from the prior year.
• Change in Accured Expenses eased to -$1.5 million in Q4 2025 per SGMOQ's latest filing, from $4.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.8 million in Q4 2023 and bottomed at -$10.2 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is -$5500.0 (2021), against an average of $772000.0.
• Biggest YoY gain for Change in Accured Expenses was 460.74% in 2022; the steepest drop was 1736.32% in 2022.
• Year by year, Change in Accured Expenses stood at $5.1 million in 2021, then slumped by 57.29% to $2.2 million in 2022, then surged by 399.03% to $10.8 million in 2023, then slumped by 65.93% to $3.7 million in 2024, then sank by 140.89% to -$1.5 million in 2025.
• Per Business Quant, the three latest SGMOQ Change in Accured Expenses figures stand at -$1.5 million (Q4 2025), $4.0 million (Q3 2025), and -$3.9 million (Q2 2025).